Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation ; volume:11 ; number:1 ; day:13 ; month:1 ; year:2021 ; pages:1-14 ; date:12.2021
Scientific reports ; 11, Heft 1 (13.1.2021), 1-14, 12.2021
- Urheber
-
Elabi, Osama
Gaceb, Abderahim
Carlsson, Robert
Padel, Thomas
Soylu-Kucharz, Rana
Cortijo, Irene
Li, Wen
Li, Jia-Yi
Paul, Gesine
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-020-80889-8
- URN
-
urn:nbn:de:101:1-2021020723375905612673
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Elabi, Osama
- Gaceb, Abderahim
- Carlsson, Robert
- Padel, Thomas
- Soylu-Kucharz, Rana
- Cortijo, Irene
- Li, Wen
- Li, Jia-Yi
- Paul, Gesine
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson’s disease
Models of α-synuclein aggregation in Parkinson’s disease
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson’s disease
Models of α-synuclein aggregation in Parkinson’s disease
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson’s disease
Models of α-synuclein aggregation in Parkinson’s disease
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models